PHARE Trial Fails to Show Noninferiority of 6 Months Trastuzumab to 12 Months, in the adjuvant treatment of Early Breast Cancer

Capsule Summary - Additional findings suggest that patients with ER-negative tumors receiving trastuzumab for 12 vs 6 months after adjuvant chemotherapy showed a marked improvement in DFS.
Source: Clinical Care Options Oncology - Breast Cancer - Category: Cancer & Oncology Source Type: research